Despite the several treatments and immunizations that have been suggested, none have been able to stop the spread of SARS-cov-2, which has been ongoing for more than two years.
In this study, we first advocate for the replacement of
pulmonary surfactant (PS) in patients who have been hospitalized to intensive
care. Acute Respiratory Distress Syndrome (ARDS) in premature neonates is
frequently treated with pulmonary surfactant, and studies have shown that it is
extremely successful. Because SARS-CoV-2 infection and ARDS, also known as
hyaline membrane disease, have many pathogenetic and symptomatological
characteristics, using pulmonary surfactant as a supplement to existing
treatments may be advantageous. Using the surfactant we suggest in our work,
even drugs with low absorption and bioavailability can be administered directly
into the most obscure alveolar areas.
Author(s) Details:
Bruno Riccardi,
Representative Lipotech, 56022 Castelfranco di Sotto (PI), Via dei
Lazzeri, 33, Italy.
Sergio Resta,
Surgeon, general surgery specialist, freelancer, 53043 Chiusi (SI),
Via Montegrappa 1, Italy.
Giacomo Resta,
Department of Pharmaceutical Sciences, Faculty of Pharmacy,
University of Perugia, Italy.
Please see the link here: https://stm.bookpi.org/CPMS-V5/article/view/7659
No comments:
Post a Comment